TNFRSF17 and Miyoshi myopathy: In a first-in-human study of AMG 420 immunotherapy (NCT02514239), which binds to BCMA on MM cells and CD3 on T cells, 42 patients received AMG 420 (0.2–800 μg/d) (Table S1).